Opportunistic mycosis
MONDO:0002312A mycosis that arises from infection in an immunologically compromised host.
Also known as: opportunistic systemic mycoses
135 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
Can a flash of light beat a blinding eye infection?
Disease control Not yet recruitingThis study tests whether a light-activated treatment called Rose Bengal photodynamic therapy can help people with a severe fungal eye infection called Fusarium keratitis. The infection can cause vision loss, and standard treatments may not always work. Participants receive either…
Phase: PHASE3 • Sponsor: Stanford University • Aim: Disease control
Last updated Aug 18, 2026 06:00 UTC
-
Can a single injection tame severe asthma in fungal allergy?
Disease control Not yet recruitingThis study is testing whether tezepelumab, an injectable medication, can help people with severe asthma caused by allergic bronchopulmonary aspergillosis (ABPA), a condition where the immune system overreacts to certain fungi. The trial will enroll 10 adults aged 18 to 75 who hav…
Phase: NA • Sponsor: Qianfoshan Hospital • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Could a shorter drug course beat a longer one for a deadly fungal infection?
Disease control Not yet recruitingThis trial is testing whether a 10-week course of fluconazole works as well as the standard 24-week course for people with HIV who have a cryptococcal infection in their blood (antigenemia) but no symptoms. It also compares starting HIV medications right away versus waiting 14 da…
Phase: PHASE3 • Sponsor: University of Minnesota • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Can a gentler antifungal drug protect liver transplant patients from deadly mold without risking organ rejection?
Disease control Not yet recruitingInvasive mold infections are a major threat to liver transplant recipients, with mortality rates as high as 90%. The standard treatment, voriconazole, can interfere with anti-rejection drugs, increasing the risk of graft loss. This trial tests whether liposomal amphotericin B (Am…
Phase: NA • Sponsor: Beijing Friendship Hospital • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
A pharmacist in the dentist's chair: could a new team approach tame stubborn mouth conditions?
Disease control Not yet recruitingThis trial tests whether adding a clinical pharmacist to dental care can improve how oral mucosal disorders — such as oral lichen planus, recurrent canker sores, burning mouth syndrome, oral thrush, and herpes infections — are managed. Dentists in some clinics will get pharmacist…
Phase: NA • Sponsor: University of Fujairah • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Could a lower dose of a common antibiotic be safer and just as effective for a deadly pneumonia?
Disease control Not yet recruitingThis study looks at whether a lower dose of the antibiotic TMP-SMX works as well as the standard dose for treating a serious lung infection called Pneumocystis pneumonia (PCP) in people who do not have HIV. The standard dose often causes side effects in more than half of patients…
Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
Vaginal device aims to boost infection treatment
Disease control Not yet recruitingThis study tests whether a vaginal ovule device, used alongside standard antibiotics or antifungals, improves vaginal health in women with bacterial vaginosis or yeast infections. Eighty women aged 18 to 60 receive either the active device or a placebo ovule over three treatment …
Phase: NA • Sponsor: ROELMI HPC • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
Blue light could soothe vaginal disorders without hormones
Disease control Not yet recruitingThis study tests whether blue LED light therapy can improve symptoms of common vaginal conditions like menopause-related dryness, bacterial vaginosis, and yeast infections. About 150 women aged 18 to 75 will receive the treatment either at home or in a clinic. Researchers will ch…
Phase: NA • Sponsor: Patricia Lordelo • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Can a cancer drug wake up immune cells to beat HIV-Related infections?
Disease control Not yet recruitingThis study tests a drug called Sintilimab, which is normally used for cancer, to see if it can help people with HIV who have infections that won't go away with standard treatment. The drug works by 'waking up' exhausted immune cells. Fifty adults with HIV and a hard-to-treat infe…
Phase: PHASE1, PHASE2 • Sponsor: Shanghai Public Health Clinical Center • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New hope for HIV patients: shorter, stronger fungal infection treatment on trial
Disease control Not yet recruitingThis study tests two new ways to treat talaromycosis, a serious fungal infection in people with HIV. It compares a single high dose of a newer antifungal drug (liposomal amphotericin B) against two weeks of the standard drug, and also checks if adding another medicine (flucytosin…
Phase: PHASE3 • Sponsor: Duke University • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New study seeks best backup plan for deadly pneumonia in immunocompromised patients
Disease control Not yet recruitingThis study looks at which second-choice treatment works best for a serious lung infection called PCP when the usual antibiotic cannot be used due to allergies, side effects, or failure. About 416 adults with weakened immune systems (from HIV, transplants, cancer, or other causes)…
Phase: PHASE4 • Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New study aims to treat deadly fungus in patients with liver issues
Disease control Not yet recruitingThis study tests a drug called liposomal amphotericin B in 40 ICU patients who have a severe fungal infection (invasive aspergillosis) and liver problems. The drug is given daily for 2 weeks, followed by 4 weeks of monitoring. The goal is to see if it is safe and effective for th…
Phase: NA • Sponsor: Southeast University, China • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Shorter steroid course for severe PCP? new trial aims to find out
Disease control Not yet recruitingThis study looks at how long steroids should be given to adults with severe Pneumocystis pneumonia (PCP), a serious lung infection common in people with weakened immune systems. About 416 participants who improve within 10 days will either stop steroids early or continue for 21 d…
Phase: PHASE4 • Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Could steroids slash death rates from a rare pneumonia?
Disease control Not yet recruitingThis study tests whether adding corticosteroids (low or moderate dose) to standard care can reduce deaths from severe Pneumocystis pneumonia (PJP) in non-HIV patients in the ICU. PJP has a very high death rate of 60-80% in this group. The trial will compare two steroid doses agai…
Phase: PHASE3 • Sponsor: Qingyuan Zhan • Aim: Disease control
Last updated Jun 26, 2026 14:24 UTC
-
Can steroids save lives in severe pneumonia? new trial aims to find out
Disease control Not yet recruitingThis trial tests whether low or moderate doses of the steroid methylprednisolone can reduce deaths in patients with severe community-acquired pneumonia. It will enroll 1500 ICU patients with pneumonia caused by adenovirus or Pneumocystis jirovecii. The study uses an adaptive desi…
Phase: PHASE2, PHASE3 • Sponsor: Qingyuan Zhan • Aim: Disease control
Last updated Jun 26, 2026 13:09 UTC
-
Can a lower dose of antibiotics prevent pneumonia just as well after kidney transplant?
Prevention Not yet recruitingThis study tests whether a lower dose of the antibiotic TMP-SMX works as well as the standard dose to prevent a serious lung infection called PJP in people who have just had a kidney transplant. About 1,084 adult first-time kidney transplant recipients will take either a low or s…
Phase: PHASE4 • Sponsor: Anhui Provincial Hospital • Aim: Prevention
Last updated Jun 27, 2026 13:00 UTC
-
Could a common steroid prevent a deadly complication in AIDS patients?
Prevention Not yet recruitingThis study tests whether a short course of the steroid prednisolone can prevent paradoxical immune reconstitution inflammatory syndrome (IRIS) in people with AIDS who have low CD4 counts and are starting HIV treatment. About 131 participants will receive either prednisolone or no…
Phase: NA • Sponsor: Shanghai Public Health Clinical Center • Aim: Prevention
Last updated Jun 27, 2026 12:29 UTC
-
New vaginal ovule aims to soothe recurrent infections
Symptom relief Not yet recruitingThis study tests a medical device called Rephegyn vaginal ovules to help treat fungal (candidiasis) and bacterial infections. The device is designed to help heal the vaginal lining and reduce symptoms like discharge, pain, and itching. About 34 adults with recurrent infections wi…
Sponsor: Innate srl • Aim: Symptom relief
Last updated Jun 27, 2026 12:07 UTC
-
Scientists hunt for clues to Drug-Resistant fungus in Patients' homes and workplaces
Knowledge-focused Not yet recruitingThis study will analyze respiratory samples from 1,000 patients in France to understand why some Aspergillus fungi become resistant to common antifungal drugs. Researchers will test samples for resistance and collect information about patients' environments, jobs, and medication …
Sponsor: Nantes University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
New study aims to improve inhaler treatment for lung fungus
Knowledge-focused Not yet recruitingThis study looks at how well an inhaled antifungal drug (liposomal amphotericin B) reaches the lungs in people with chronic pulmonary aspergillosis, a long-term lung infection. About 18 adults will inhale two different doses on separate days and then have special scans to see whe…
Phase: PHASE1 • Sponsor: Radboud University Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:07 UTC
-
Tailoring antifungal doses for seniors: a precision approach
Knowledge-focused Not yet recruitingThis study aims to find the best dose of isavuconazole, an antifungal drug, for patients over 60 with invasive fungal infections. Researchers will monitor drug levels in the blood and adjust doses to improve treatment and reduce side effects. The goal is to create personalized do…
Sponsor: Chinese PLA General Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC
-
ICU fungus study aims to uncover resistance secrets
Knowledge-focused Not yet recruitingThis study will look at Candida fungi from 300 patients in a hematology ICU. Researchers want to see how often these fungi form biofilms (slimy layers that protect them) and whether that makes them resistant to antifungal drugs. The goal is to learn which Candida types are most c…
Sponsor: Assiut University • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:59 UTC